Human immunodeficiency virus-associated dementia

Archives of Neurology

Volumn 57, Issue 3, 2000, Pages 321-324

  Clifford, David B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0034092005     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.3.321     Document Type: Article

References (20)

1. Working Group of the American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Neurology. 1991;41:778-785.
2. Ellis RJ, Deutsch R, Heaton RK, et al for the San Diego HIV Neurobehavioral Research Center Group. Neurocognitive impairment is an independent risk factor for death in HIV infection. Arch Neurol. 1997;54:416-424.
3. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL, the AZT Collaborative Working Group. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1988;319:1573-1578.
4. Pizzo PA, Eddy J, Falloon J. et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988;319:889-896.
5. Navia BA, Jordan BD, Price RW. The AIDS dementia complex, I: clinical features. Ann Neurol. 1986;19:517-524.
6. Portegies P, de Gans J, Lange JMA, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ. 1989;299:819-821.
7. Gray F, Bélec L, Keohane C, et al. Zidovudine therapy and HIV encephalitis: a 10-year neuropathological survey. AIDS. 1994;8:489-493.
8. Sacktor NC, Lyles RH, McFarlane G, et al. HIV-1-related neurological disease incidence changes in the era of highly active antiretroviral therapy. Neurology. 1999;52:A252-A253.
9. Sacktor NC, Lyles RH, McFarlane G, et al, for The Multicenter AIDS Cohort Study. The changing incidence of HIV-1 related neurologic diseases: 1990-1997. In: Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 145.
10. Ferrando S, van Gorp W, McElhiney M, Goggin K, Sewell M, Rabkin J. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS. 1998;12(suppl):F65-F70.
11. Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology. 1999;52:607-613.
12. Sidtis JJ, Gatsonis C, Price RW, et al, for the AIDS Clinical Trials Group. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann Neurol. 1993;33:343-349.
13. Freeman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141-145.
14. Brew BJ, Brown SJ, Catalan J, et al. Phase III, randomized, double-blind, placebo-controlled, multicentre study to evaluate the safety and efficacy of abacavir (ABC, 1592) in HIV-1 infected subjects with AIDS dementia complex (CNA3001). In: Abstracts of the 12th World AIDS Conference; June 29-July 2, 1998. Geneva, Switzerland.
15. Lipton SA. Neuronal injury associated with HIV-1: approaches to treatment. Annu Rev Pharmacol Toxicol. 1998;38:159-177.
16. Navia BA, Dafni U, Simpson D, et al, for the AIDS Clinical Trials Group. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology. 1998;51:221-228.
17. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Safety and tolerability of the antioxidant OPC-14,117 in HIV associated cognitive impairment. Neurology. 1999;49:142-146.
18. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Neurology. 1998;50:645-651.
19. Schifitto G, Sacktor N, Marder K, et al, for The Neurological AIDS Research Consortium. Randomized, placebo-controlled trial of the PAF antagonist lexipafant in HIV-associated cognitive impairment. Neurology. 1999;53:391-396.
20. Heseltine PNR, Goodkin K, Atkinson et al. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol. 1998;55:41-51.